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ABSTRACT
The effects of electronic-cigarette use (vaping), marketed as a healthier 
alternative to cigarette smoking (CS), on lung function remain equivocal. 
Therefore, this study assessed and compared the effects of vaping and CS 
on maximum respiratory pressures (MRP), respiratory function and car-
boxyhaemoglobin levels. Forty-four young healthy participants were 
recruited: vapers (n = 12), cigarette smokers (n = 14), and people who 
had never vaped nor smoked (control) group (n = 18). Spirometry, MRP 
and carboxyhaemoglobin levels were measured. Both smokers and vapers 
had a lower Forced expiratory volume in the first second (FEV1), Peak 
expiratory flow, FEV1/Forced vital capacity (FEV1/FVC), Forced expiratory 
flow at 25%, 25–75% of FVC, FEF25-75pred% and higher carboxyhaemo-
globin% than controls (p < 0.05). In smokers, but not in vapers, FEV1pred% 
was lower than in controls (p < 0.01). MRP did not differ significantly 
between the three groups. Vaping has similar detrimental effects as CS on 
pulmonary function and may thus not be a healthier alternative to 
smoking.
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Cigarette smoking is a well-known risk factor for the development of cancer, cardiovascular 
diseases and respiratory disorders, such as lung cancer and chronic obstructive pulmonary 
disease (COPD) (Barengo et al., 2019). Smokers are very much aware of these dangers and 
many of them seek to quit smoking. Electronic cigarettes (e-cigarette) are marketed as 
a healthier alternative to cigarette smoking, as they are devices that do not burn tobacco, 
yet may deliver nicotine, and contain fewer than the more than 4000 toxic chemicals in 
cigarette smoke (Glantz & Forbes, 1996; Ling & Glantz, 2005; Richter et al., 2008). In the 
United Kingdom (UK) e-cigarettes are marketed as a smoke cessation product, whereas in the 
United States (US) they are marketed to young adults as an alternative for those who do not 
smoke (Mantey et al., 2016). It was reported that vaping prevalence has substantially increased 
among youth (Levy et al., 2019). This raise concerns about the creation of a new generation of 
nicotine-dependent population who could easily change to cigarette smoking. The success of 
e-cigarettes to help quit smoking is reflected by the fact that 54% of e-cigarette users in the UK 
are ex-smokers (Action on Smoking and Health, 2019).
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An e-cigarette is a battery-powered device that consists of a vaporizing chamber, a cartridge/ 
tank that contains the vaping liquid (e-liquid) and an atomizer that heats, rather than burns, the 
e-liquid that consists of vegetable glycerine, propylene glycol and other chemicals, and may 
contain nicotine. When the e-liquid is heated, it produces the aerosolized vapour that is inhaled 
by the vaper. Because vaping is a relatively new phenomenon, the impact of vaping on health has 
not yet thoroughly been investigated. However, the few studies that have investigated vaping 
indicate that e-cigarettes have detrimental effects on human health in general and on lung 
function in particular (Antoniewicz et al., 2019; Chaumont et al., 2019; Coppeta et al., 2018; 
Mohammad Z. Darabseh et al., 2020; Meo et al., 2019). Interestingly, some reports found that 
vaping is linked with lung injury, named ‘E-cigarette, or vaping product use-associated lung injury’ 
(EVALI) including inducing pneumonia, hypersensitivity pneumonitis, lipoid pneumonia and dif-
fuse alveolar damage (Henry et al., 2020; Landman et al., 2019). This problem can not be ignored, 
as reflected by the 2,807 hospitalized EVALI, mostly young adults and/or teenagers, cases or deaths 
that have been reported in the US, and the 244 suspected adverse reactions reported, including 
two fatal outcomes, in the UK (Centers for Disease Control Prevention & Information, 2020; UK 
Medicines and Healthcare products Regulatory Agency, 2020). Thus, although Public Health 
England claimed that e-cigarettes are 95% safer than cigarette smoking (McNeill et al., 2015) 
and the prevailing idea is that vaping is not only safer, but also helps in smoking cessation (McNeill 
et al., 2015), it is far from clear that vaping is a healthier alternative than smoking. Therefore, the 
aim of this study was to compare the effects of vaping and smoking on lung function. It was 
hypothesized that vaping has less detrimental effects on pulmonary function than smoking.
Methods
Study design
This was a laboratory-based, cross-sectional, observational study to compare pulmonary function in 
i) vapers, ii) cigarette smokers and iii) people who neither smoked nor vaped (controls). Ethical 
approval was obtained from the Science and Engineering Research Ethics and Governance 
Committee at Manchester Metropolitan University (EthOS reference number: 5944). All procedures 
adhered to the principles stated in the Declaration of Helsinki and all participants provided written 
informed consent before participating.
Participants
The sample size was based on the work of (Polosa et al., 2017) who compared vapers with 
smokers. Using their numbers, 7 participants per group were needed to detect a 12% difference 
in Forced Expiratory Volume in one second (FEV1) with a power of 80% and a type-I error (alpha) of 
0.05 (5%).
Participants were recruited from the local community and Manchester Metropolitan University 
through posters, social media channels and snowball sampling. The inclusion criteria were: 18- to 55- 
year-old men and women, and cigarette smokers and vapers had to have smoked/vaped for ≥1 year. 
Exclusion criteria were: neuromuscular disease; severe musculoskeletal injuries; any lower limb 
injury; any diagnosed mental health disorder; treatment for chronic respiratory complaints; 
a known history of heart disease; smokers who mix cigarette and vape; water pipe (shisha) smokers. 
Vaping and smoking history and volume were assessed by a questionnaire. The smoking volume (SV) 
was given as pack years, calculated as: 
SV ¼ Ncig � S
  �
=20 
Where Ncig is the current number of cigarettes smoked per day, and S the number of years smoked.
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Participant characteristics
Demographic data including age, sex, height, body mass, body mass index (BMI) and occupation of 
participants was recorded. Height and body mass were assessed using a stadiometer and digital 
scales, respectively. Body composition was assessed using bioelectrical impedance (BodyStat 1500, 
BodyStat, Douglas, UK).
Carboxyhaemoglobin
HbCO, which is the percentage of the haemoglobin (Hb) oxygen binding sites occupied by carbon 
monoxide (CO), was measured with a hand-held CO metre (Micro Smokerlyzer, Bedfont Scientific Ltd.; 
Kent, UK) according to the recommendations of the manufacturer (Hajek & Belcher, 1991). Participants 
exhaled to residual volume and then quickly inhaled until total lung capacity. After a 15-s breath-hold, 
the participants were asked to exhale slowly through a disposable mouthpiece attached to the carbon 
monoxide metre for at least 10 s. The measured HbCO level was expressed as percentage (HbCO%).
Spirometry
Spirometry was conducted using a Micro Medical Spiro USB Spirometer and analysed with Spida 5 
software (Cardinal Health, UK). FEV1, Forced Vital Capacity (FVC), FEV1/FVC ratio, Peak Expiratory Flow 
(PEF), maximum mid-expiratory flow between 25% and 75% of the FVC (FEF25-75%) and predicted 
values of FVC, FEV1, FEF25-75% were recorded. The spirometry was completed in accordance with the 
American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines (Miller et al., 2005). 
Predicted values were calculated by the Spida 5 software based on body mass index, age, sex and 
ethnicity according ATS/ERS guidelines. Each participant had a nose clip and completed a minimum 
of three manoeuvres with at least 1–2 min rest between each manoeuvre. Manoeuvres were rejected 
if: participants prematurely stopped exhalation, coughed during the first second of exhalation, lips 
were not fully sealed around the mouthpiece, the mouthpiece was obstructed by the teeth or 
tongue and/or the effort appeared submaximal. The test session was concluded when the largest 
two FEV1 and the largest two FVC were each within 0.15 L of each other in at least 3 manoeuvres 
(Miller et al., 2005). If these criteria were not met, the manoeuvres were repeated until the criteria 
were met, eight manoeuvres had been attempted, or if the participant did not want to continue. 
Participants were instructed not to eat heavy meals or to smoke or vape and to refrain from vigorous 
physical activity for at least two hours before the test.
Respiratory pressure
The maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and sniff nasal inspiratory 
pressure (SNIP) were determined using a portable mouth pressure device (MicroRPM, Cardinal 
Healthcare, UK). The participants were asked to inhale (MIP/SNIP) or exhale (MEP) as forcefully as 
possible after full exhalation or inhalation, respectively into the portable MicroRPM. To determine 
SNIP, participants placed a probe in one of their nostrils, and with the other nostril closed inhaled as 
forceful as possible via the nose (Lofaso et al., 2006). For all manoeuvres, attempts were repeated, 
with a 30-s interval between each attempt to prevent the development of respiratory muscle fatigue, 
until a maximum value was reached.
Statistics
Statistical analyses were performed using SPSS 24.0 (IBM Corporation, NY, US). Data was assessed for 
normality with the Shapiro-Wilk tests. If the data were not normally distributed an Analysis of 
variance (ANOVA) was performed on the log-transformed data. Differences between vapers, smokers 
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and controls, and sexes were tested using two-way univariate ANOVA with as between factors group 
and sex. If a significant group effect or a group * sex interaction were found, a Tukey 2-sided post-hoc 
test was performed to locate the significant differences. Predicted spirometry values were compared 
between pure vapers (who never smoked), vapers who were ex-smokers and controls with a two- 
way ANOVA and Tukey-corrected post-hoc tests to locate the differences. A stepwise regression 
analysis was performed to assess to what extent spirometry parameters were affected by sex, and 
vaping or smoking duration or volume. Differences and correlations were considered significant at 
p < 0.05. All data are presented as mean±SD unless stated otherwise.
Results
Men were taller and heavier than women, and women had a higher fat percentage than men 
(p < 0.05), irrespective of being vapers, smokers or controls (Table 1). All vapers had used e-cigarettes 
daily for ≥ 1 year (1.67 ± 1.00 years). Eleven of the twelve vapers were using nicotine-containing 
e-liquids with a concentration ranging between 3 to 18 mg/mL. The puffs per e-cigarette were 
8.30 ± 5.23. Seven out of twelve vapers were former smokers. All cigarette smokers had smoked daily 
for 4.86 ± 2.49 years, consumed 9.00 ± 4.78 cigarettes/day and had a smoking history of 2.29 ± 1.88 
pack years. No group-sex interactions were found for any outcome measure, indicating that all the 
observed effects of smoking and vaping were similar in men and women.
Men had higher FEV1, FVC, PEF, FEF25%, FEF50%, FEF25-75%, MIP and MEP than woman (p < 0.05) 
(Table 2 and Figure 1 and 2). FEV1pred%, FEV1/FVC, FEF75%, FEF25-75pred%, SNIP and HbCO% did, 
however, not differ significantly between men and women (Table 2 and Figure 1 and 2), but the 
FVCpred% was higher in women than men (Table 2; p < 0.03).
Vapers and cigarette smokers had lower FEV1, PEF, FEV1/FVC, FEF25%, FEF50%, FEF25-75%, FEF25-75pred% 
and higher HbCO% than controls (p < 0.05) (Table 2 and Figure 1 and 2). The FEV1pred% was lower in 
smokers than controls (p < 0.01), but there was no significant difference between vapers and controls 
(p = 0.054) (Figure 1). Vapers had a lower FEF75% than controls (p < 0.009), but there was no significant 
difference in FEF75% between smokers and controls (p = 0.064) (Figure 2).There were no significant 
differences in FEV1, FEV1pred%, PEF, FEV1/FVC, FEF25%, FEF50%, FEF75%, FEF25-75%, FEF25-75pred% and HbCO 
% between vapers and smokers (Table 2 and Figure 1 and 2). The FVC, FVCpred%, MIP, MEP and SNIP did 
Table 1. Participant characteristics.
Vapers Cigarette smokers Controls
Men (n = 6) Women 
(n = 6)
Men (n = 8) Women 
(n = 6)
Men (n = 9) Women 
(n = 9)
Age (Years) 20.7 ± 1.5 20.3 ± 1.6 21.5 ± 2.1 20.0 ± 1.1 24.3 ± 8.6 21.3 ± 1.9
Height (m) 1.74 ± 0.10 1.58 ± 0.04* 1.71 ± 0.05 1.59 ± 0.05* 1.79 ± 0.08 1.64 ± 0.06*
Mass (kg) 74.7 ± 10.0 57.0 ± 5.1* 73.0 ± 25.8 65.5 ± 9.3* 78.4 ± 13.3 68.7 ± 17.6*
BMI 24.6 ± 3.1 22.8 ± 2.2 24.5 ± 7.3 25.9 ± 4.4 24.0 ± 2.9 25.1 ± 5.4




2.1 ± 1.1 (6) 1.1 ± 0.4 (6) - - - -
Puffs per e-cigarette single 
use
10.2 ± 6.7 
(5)





- - 5.4 ± 2.9 (7) 4.1 ± 1.7 (6) - -
Cigarettes 
per day




- - 2.7 ± 2.3 (7) 1.7 ± 1.0 (6) - -
BMI: body mass index; (x): number of participants; *significantly different from men at p < 0.05.
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not differ significantly between vapers, smokers and controls (Table 2). The FEV1/FVC (p ≤ 0.033), 
FEF25-75pred% (p ≤ 0.009) and HbCO% (p < 0.001) were lower in pure vapers and vapers who were ex- 
smokers than controls, with no significant difference in these parameters between pure vapers and 
vapers who were ex-smokers (Table 3).
A stepwise linear regression was performed to assess to what extent the respiratory parameters 
were determined by sex, height, body mass, smoking duration, smoking volume, or for vapers, 
vaping duration and number of puffs. Smoking duration was the primary determinants of FEV1pred% 
(R2adj = 0.564; p = 0.002), FEV1/FVC (R
2
adj = 0.568; p = 0.002), FEF50% (R
2
adj = 0.412; p = 0.011), 
FEF25-75% (R
2
adj = 0.528; p = 0.003), FEF25-75pred% (R
2
adj = 0.665; p < 0.001) (Figure 3). Vaping duration 
and number of puffs were not significant determinants of pulmonary function (Figure 3).
Discussion
The main observation of this study was that smokers and vapers had a similarly lower respiratory 
function compared to people who neither smoked nor vaped, irrespective of sex. This was not 
related to respiratory muscle weakness, as reflected by similar maximal respiratory pressures in all 
groups. In addition, the HbCO content was similarly elevated in smokers and vapers. These data 
indicate that vaping and smoking may cause a similar degree of airway obstruction.
Figure 1. A) FEV1/FVC: Forced expiratory volume in one second/ forced vital capacity; b) FEV1: Forced expiratory volume in 
one second; c) FEV1 predicted: Forced expiratory volume in one second predicted %; d) PEF: Peak expiratory flow; * sex difference 
at p < 0.001; α: significantly different from control at p ≤ 0.008.
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In this study we confirmed that men have higher spirometric values, such as FEV1 and FVC, than 
women, as reported previously (Mohammad Z Darabseh et al., 2021; Mead, 1980; Zakaria et al., 2019). 
Although it has been reported that cigarette smoking affects pulmonary function more in women 
than in men (Xu et al., 1994), the absence of any significant group-sex interaction indicated that in 
our study the effects of smoking and vaping described below were similar in men and women.
Figure 2. A) FEF25%-75%: Forced expiratory flow at 25%-75%; b) FEF25%: Forced expiratory flow at 25%; c) FEF25%-75% (pred): Forced 
expiratory flow at 25%-75% predicted %; d) FEF75%: Forced expiratory flow at 75%; * sex difference at p ≤ 0.013; α: different from 
control at p ≤ 0.008.






pure vapers and vapers ex-smokers vs. 
controls
p (p-value) 
pure vapers vs. vapers ex- 
smokers
FEV1/FVC (%) 80.0 ± 4.0 82.0 ± 3.0 0.033 0.26
FEF25-75% 
(pred)
60.0 ± 35.0 81.0 ± 15.0 0.009 0.18
HbCO (%) 1.08 ± 0.29 0.96 ± 0.13 <0.001 0.33
All data are presented as (mean±SD); FEV1/FVC: Forced expiratory volume in one second/ forced vital capacity; FEF: Forced 
Expiratory Flow; HbCO: Carboxy-haemoglobin; (x): number of participants. Controls data are in Figures 1 and 2.
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Previous studies have also shown that vaping reduces lung function to a similar extent as smoking 
(Antoniewicz et al., 2019; Coppeta et al., 2018; Mohammad Z. Darabseh et al., 2020; Meo et al., 2019), 
but other studies have reported no changes in pulmonary function parameters after vaping (Polosa 
et al., 2017; Staudt et al., 2018; Vardavas et al., 2012). The discrepancy between these studies might 
be due to the duration of e-cigarette use (i.e. years), whether participants were former smokers and/ 
or the duration of smoking or frequency/intensity of vaping. Here we found that the duration of 
smoking was associated with a decline in respiratory function, but this was not the case for vaping. In 
fact, we observed that people who had been vaping for as little as 1.67 years had a similar decrement 
in lung function as those who had smoked for 4.86 years. This decline was not attributable to 
a previous smoking history in the vapers, as we found that there was no significant difference in 
spirometry between pure vapers and vapers who were ex-smokers. These decrements in spirometry 
measures are indicative of mild airway obstruction (McFadden & Linden, 1972; Stockley et al., 2017). 
Figure 3. Relationship between respiratory parameters and smoking/vaping duration. a) FEF25%-75% (pred): Forced expiratory flow 
at 25%-75% predicted; b) FEV1pred%: Forced expiratory volume in one second predicted%; c) FEV1/FVC: Forced expiratory volume 
in the first second/ forced vital capacity. p-value significant at p < 0.05.
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The increase in airflow resistance may be due to small airway narrowing consequent to mucosal 
oedema, smooth muscle contraction and/or local secretions as seen in long-term smokers (Vardavas 
et al., 2012) and may thus be an early sign of potential progression into obstructive lung diseases.
Another explanation for low airflow could be reduced respiratory muscle strength. However, 
there were no significant differences between controls and vapers/cigarette smokers in maximal 
inspiratory and expiratory pressures. These findings suggest that the reduced airflow during smok-
ing/vaping is a consequence of obstruction of the airways rather than lower respiratory muscles 
strength. We have seen previously that elevated HbCO results in an earlier onset of muscle fatigue 
(Morse et al., 2008) and it can therefore not be excluded that during exercise respiratory muscle 
fatigue may impair lung function in smokers and vapers.
Limitations of this study include the small sample size, although power calculations indicated that 
the sample size was large enough to detect 12% differences in FEV1. Perhaps a larger problem is that 
some of the participants were ex-smokers. However, even in vapers who had no smoking history the 
FEV1/FVC and FEF25-75%pred were lower than that in controls. Further studies are needed to compare 
vapers who never smoked with smokers and assess the effects of smoking and vaping cessation on 
ventilatory function.
Conclusion
While neither vaping nor smoking had a significant impact on respiratory muscle strength, both 
vaping and smoking led to a similar obstruction of the airways, independent of sex. The elevated 
HbCO in both vapers and smokers may further compromise respiratory function during exercise. 
These observations indicate that vaping has similar detrimental effects on pulmonary function as 
smoking and suggest that one should treat the suggestion that vaping is 95% healthier than 
smoking with caution (McNeill et al., 2015). In addition, increasing vaping uptake among youth 
could stimulate uptake of cigarette smoking, creating a smoking-dependent generation.
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